Published in AIDS Weekly, February 21st, 2005
"The distribution of secretory leukocyte protease inhibitor (SLPI) at entry portals indicates its involvement in defending the host from pathogens, consistent with the ability of SLPI to inhibit human immunodeficiency virus (HIV)-1 infection by an unknown mechanism.
"We now demonstrate that SLPI binds to the membrane of human macrophages through the phospholipid-binding protein, annexin II," wrote investigators from the United States.
"Based on the recent identification of human cell membrane phosphatidylserine (PS) in the outer coat of HIV-1," G. Ma and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.